Abstract: This disclosure relates to a targeted PEGylated liposomal gemcitabine (PLG) composition comprising a PEGylated liposome encapsulating one or more agents comprising gemcitabine and a targeting moiety; pharmaceutical composition and methods comprising PLG or producing PLG; and manufacturing equipment for performing the methods.

Abstract: Disclosed herein are compositions including an aptamer bound to a complex, wherein the complex comprises at least two polypeptides. Accordingly, methods of using the aptamers and making the aptamers are also disclosed.

Abstract: Provided herein are compositions including peptide or nucleic acids encoding peptides and related methods for the treatment of angiogenic conditions such as cancer, vascular disorders such as cardiovascular disorders, and infectious disease.

Abstract: The insert shelf (1) is characterized in that it has at least one means (3) with which an incubation medium located in an incubation vessel placed on the insert shelf (1) can be set in motion during an incubation treatment or during an incubation process in an incubator (2). For this purpose, the at least one means (3) can be operated electrically and/or preferably moved mechanically.

Abstract: The invention generally relates to protein standard compositions and methods of making the same. Also contemplated are kits including the protein standard compositions or kits for making the protein standard compositions and methods of using the protein standard compositions to quantify the abundance of a phosphorylated protein in a sample.

Abstract: The invention provides a fermented Pennisetum extract, which has an advantageous effect in treating and preventing a cancer without toxicity to normal cells. The invention also provides a process of preparing the fermented Pennisetum extract and the application of the fermented Pennisetum extract in the treatment or prevention of a cancer.

Abstract: The present invention provides devices, systems, and methods for rapid and easy-to-use in sample thermal cycling or temperature changes for the facilitation of reactions such as but not limited to PCR.

Abstract: Methods and systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.

Abstract: Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.

Abstract: Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.

Abstract: The invention provides methods and kits for detecting the presence of, the amount of, or the concentration of a substantially non-emitting metal in a sample by a) providing a sensitizer to a chelator of the substantially non-emitting metal thereby creating a sensitized-metal complex; b) adding an unsensitized chelate, and c) detecting a signal from the unsensitized chelate. The substantially non-emitting metal may be gadoliniumn and may exist in complex with a chelator. The unsensitized chelate may be terbium (Tb) or europium (Eu) and the detecting a signal may be performed by fluorescence.

Abstract: Compounds with amino amide linkers and pharmaceutical compositions and medicaments comprising such compounds are disclosed. In addition, methods of making such compounds and their uses for treating or ameliorating diseases, disorders, or conditions associated with protein malfunction, such as cancer, are provided.

Abstract: The present invention provides methods for assessing the likelihood of effectiveness of chemotherapy such as oxaliplatin treatment in colorectal cancer patients as well as their survival prospect by determining the level of miR-133a in the cancer tissue. A kit useful for such methods are also provided.

Abstract: Apparatuses and methods for removing magnetic particles from suspensions are described. One embodiment of the apparatus is called a magnetic needle.

Abstract: The present invention pertains to a polyclonal or monoclonal antibody specifically binding to BoNT/E-cleaved SNAP-25.

Abstract: The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Abstract: Materials and methods of modifying an electrode surface are described herein. Self-assembled monolayers (SAM) of polyaromatic molecules covalently attached and form a graphitic-like surface on the electrode surface. After covalent attachment of the polyaromatic monolayer to the surface, polyaromatic-functionalized molecular species is physisorbed onto the surface using the ?-interactions. This concept can be applied to generate high performance electrode materials modified with molecular species. The electrode materials can be applied in photoelectrochemical cells, electrochemical cells, sensors, and electrochromic materials. This approach overcomes the major synthetic challenges to modifying surfaces with molecular species, in addition to protecting the surfaces from corrosion.

Abstract: A cytometer includes an avalanche photodiode, a switching power supply, a filter, and voltage adjustment circuitry. The switching power supply includes a feedback loop. The filter is electrically connected between the switching power supply and the avalanche photodiode. The voltage adjustment circuitry adjusts a voltage on the feedback loop based at least in part on a voltage measured between the filter and the avalanche photodiode.

Abstract: The invention provides methods for characterizing a target protein wherein a mass spectrum of digest peptides of the target protein is acquired and compared with measured reference mass spectra of digest peptides of reference proteins or of proteins of reference host cells. The comparison comprises determining similarity scores of the intensity patterns of the mass spectrum and the reference mass spectra. The characterization comprises assigning the target protein to a reference protein having a reference mass spectrum with a similarity score above a predetermined threshold.

Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.

Abstract: The invention relates to a new type of element encoded particles suitable for the attachment of bio molecules to enable massively multiplex bio-analytical methods, and to calibrate and tune the elemental flow cytometer mass spectrometer (FC-MS).

Abstract: Computing systems and methods for characterizing a protein are provided. Each residue in a subset of the protein is in an amino acid type set and is represented by a vertex in a graph G formed from an atomic model of the protein. NMR data, acquired with some of the residues of the protein isotopically labeled, is used to form a graph H with each vertex representing a different residue of the protein and assigned one or more amino types. Placements of H onto G are formed, each including mappings assigning vertices in H to vertices in G subject to the constraints that vertices in H mapped to vertices in G cannot be of different amino acid types and edges between pairs of vertices in H must map to corresponding edges in G. For each vertex in H, the number of different valid mappings to G is determined by polling the placements as a constraint satisfaction problem and is deemed assigned when only a single unique assignment is identified.

Abstract: Insulin-like growth factor-binding protein 7 (IGFBP7) has been identified herein as a therapeutic target for the treatment or prevention of heart diseases, metabolic diseases, and other related disease or conditions. IGFBP7 inhibitors having IGFBP7 expression and/or activity reducing properties are described herein. Treatment methods, and uses, relating to such IGFBP7 inhibitors for the treatment or prevention of heart failure, IGFBP7-related metabolic diseases, and related diseases or conditions are provided.

Abstract: For patients who exhibit or may exhibit primary or comorbid disease, pharmacological phenotypes may be predicted through the collection of panomic data over a period of time. A machine learning engine may generate a statistical model based on training data from training patients to predict pharmacological phenotypes, including drug response and dosing, drug adverse events, disease and comorbid disease risk, drug-gene, drug-drug, and polypharmacy interactions. Then the model may be applied to data for new patients to predict their pharmacological phenotypes, and enable decision making in clinical and research contexts, including drug selection and dosage, changes in drug regimens, polypharmacy optimization, monitoring, etc., to benefit from additional predictive power, resulting in adverse event and substance abuse avoidance, improved drug response, better patient outcomes, lower treatment costs, public health benefits, and increases in the effectiveness of research in pharmacology and other biomedical fields.

Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.

Abstract: A feces sampling container having an increased storage stability of a component in a feces sample such as hemoglobin to enable the measurement of a component in a feces sample with a small amount of feces collected. The container includes a container body, and a feces sampling stick having a gripping part on one side and a stick part on the other side, the stick part having a feces sampling part in the vicinity of the tip, wherein the container body comprises an opening part through which the feces sampling part of the feces sampling stick is inserted, and a feces container chamber in which a desiccant is enclosed, wherein the feces sample held by the feces sampling part is dried by a contact of the feces sampling part, which is inserted through the opening part and holding the feces sample, with the desiccant.

Abstract: The invention relates to an enzymatically responsive product that includes an amino acid residue conjugated to a magnetic particle, wherein the amino acid residue is phosphorylated or sulfated or comprises an ester-moiety linked via peptide bond. Compositions containing the enzymatically responsive product, and the use thereof for separating distinct types of mammalian cells (e.g., cancer cells from normal cells), for treating a cancerous condition, and imaging cancer cells are also disclosed.

Abstract: The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.

Abstract: Antibiotics (Abx) are the world's most misused drugs. Antibiotics misuse occurs when the drug is administered in case of a non-bacterial infection (such as a viral infection) for which it is ineffective. Overall, it is estimated that 40-70% of the worldwide Abx courses are mis-prescribed. The financial and health consequences of Abx over-prescription include the direct cost of the drugs, as well as the indirect costs of their side effects, which are estimated at >$15 billion annually. Furthermore, over-prescription directly causes the emergence of Abx-resistant strains of bacteria, which are recognized as one of the major threats to public health today. This generates an immediate need for reliable diagnostics to assist physicians in correct Abx prescription, especially at the point-of-care (POC) where most Abx are prescribed. Accordingly, some aspects of the present invention provide methods using biomarkers for rapidly detecting the source of infection and administrating the appropriate treatment.

Abstract: Biomarker signatures for predicting breast cancer tumor aggressiveness. The signatures are derived from QTA-based parameters from a first population of low risk scores and a second population of high risk scores. The signatures may be expressed in the form log (RS)=Mx+B for linear modeling, or for logistic modeling the signatures may be expressed as either p=ex/[1+ex] where x=Ay+B, or in the form log it(p)=C(PR)+Ay+B, where y is a QTA based parameter.

Abstract: The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform for increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.

Abstract: An apparatus for pretreatment of a desired sample in a discrete fluid analyzing instrument includes a frame rotatably mounted on or within the discrete fluid analyzing instrument with a column for immobilizing at least one substance or analyte from the sample. The substance or analyte is reversibly immobilized. A first fluid transport line is provided for aspirating the sample into the column and for ejecting the substance or analyte eluted from the column. A pump is provided for pumping the sample through the column with a second fluid transport line connecting the pump to the column. A member is providing to supply the eluted substance or analyte to the discrete fluid analyzing instrument for measurement of at least one property of the substance or analyte. A device is provided for simultaneously or consecutively directing any non-pretreated sample or any subsample directly to the discrete fluid analyzing instrument.

Abstract: Provided herein are methods for identifying new biomarkers for various diseases using proteomics, peptidomics, metabolics, proteoglycomics, glvcomics, mass spectrometry and machine learning. The present disclosure also provides glycopeptides as biomarkers for various diseases such as cancer and autoimmune diseases.

Abstract: Macromolecular imprinted silica particles (“MIP”) in the presence of polymer grafted carbon black are disclosed. The disclosed molecular imprinted beads can detect disease in body fluids. For the silica gel matrix, tetraethyl orthosilicate (TEOS) was used as the backbone monomer and 3-aminopropy/triethoxysilane (APS) as a functional monomer. Carbon black was added to the sol-gel process, yielding black silica particles. Furthermore, sodium dodecyl sulfate (SDS) was used as a structure-directing agent to increase network diffusion of the template. A total of 16 MIPs were synthetized in parallel with variables that evaluate the role of key reactants in the synthesis procedure. Agglomeration tests were performed with all 16 MIPs in the presence of their template, alongside their respective controls using only phosphate buffered saline (“PBS”). Each of the MIPs was evaluated using a novel device capable of simultaneously measuring up to four samples for near infrared transmission.

Abstract: Various embodiments disclosed relate to a sensor assembly probe for determining enzymatic activity. The sensor assembly probe includes one or more fluorescent hydrophobic semi-conductive nanoparticles disposed in an aqueous medium. The assembly further includes an amphiphilic polymer including a substrate for a predetermined enzyme. The amphiphilic polymer coats at least a portion of a surface of the fluorescent hydrophobic semi-conductive nanoparticle.

Abstract: Disclosed herein are microorganisms that have enhanced tolerance to toxic compounds found in thermochemical waste streams. Methods of utilizing carbon found in waste streams are also disclosed. Also presented herein are methods for detoxifying waste streams and methods of bioconversion of toxic waste stream materials into useful products.

Abstract: A multilayered film for performing spectroscopic measurements in a fluid are provided. The multilayered film includes a substrate; a porous layer adjacent to the substrate; and a reflective layer formed on the porous layer, wherein the porous layer selectively allows a component of a fluid to be optically measured when the multilayered film is immersed in the fluid. A sensor for spectroscopic measurements in crude oil samples including a multilayered film as above is also provided. A method of manufacturing a multilayered film for spectroscopic measurements in fluids as above is also provided.

Abstract: A system and method for sensing and analyzing antibody blocking interactions is described. A biosensor can be used to identify interactions between antibodies to generate interaction profiles for the antibodies. A processor can be used to assign the antibodies to one or more bins, with the antibodies sharing a common interaction profile assigned to a common bin, and each antibody only being assigned to one bin. The antibodies can be represented by displaying nodes grouped together for antibodies in a common bin. Connections between the nodes can be displayed, representing interactions between the antibodies.

Abstract: Definitive diagnosis and early start of treatment cannot be made for tuberculosis since conventional methods for detecting a Mycobacterium tuberculosis complex require a long time plus enormous labor and expense. Because detection is difficult to perform directly from a biological sample, if the biological sample contains no or a very small amount of MPT64, there is a risk infection with the Mycobacterium tuberculosis complex will be missed. The present method and a kit address these long-standing needs by more rapidly and conveniently detecting a Mycobacterium tuberculosis complex, without culturing a biological sample containing the Mycobacterium tuberculosis complex, in which a biological sample is subjected to a heat-treatment so as to extracellularly secrete a Mycobacterium tuberculosis complex-specific secretory protein, particularly, MPB64, and subjecting the resulting treated sample to an immunological measurement/assay.

Abstract: Provided are: an Fc-binding protein having improved stability, particularly to heat and acid; a method for producing the protein; an antibody adsorbent using the protein; and a method for separating the antibodies using the adsorbent. Specifically provided are: an Fc-binding protein having improved stability to heat and acid, achieved by substituting an amino-acid residue in a specific position in the extracellular region of human FcyRIIIa with another specific amino acid; a method for producing the protein; an antibody adsorbent using the protein; and a method for separating the antibodies using the adsorbent.

Abstract: Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide and 3,4,-dichloro-N-[2-(methylamino)cyclohexyl]-N-methylbenzamide, as well as the precursory immunogens, are described.

Abstract: The subject technology relates generally to compositions and methods for producing plasmid DNA of a desired quality. In addition, it relates to the discovery of Escherichia coli (E. coli) bacteria with a constitutive methylase gene stably incorporated into the chromosomal DNA and uses thereof.

Abstract: A system for assaying forces applied by cells includes an optically transparent substrate comprising a soft material having a Young's modulus within the range of about 3 kPa to about 100 kPa. An array of molecular patterns is disposed on a surface of the optically transparent substrate, the molecular patterns include fluorophore-conjugated patterns adherent to cells. The system includes at least one light source configured to excite the fluorophore-conjugated patterns and an imaging device configured to capture fluorescent light emitted from the fluorophore-conjugated patterns. Dimensional changes in the size of the patterns are used to determine contractile forces imparted by cells located on the patterns.

Abstract: The present invention relates to a method of estimating the number of urinary podocytes, including detecting podocalyxin in a urinary sediment sample liquid, and more specifically, to a method of estimating the number of urinary podocytes, including the following steps (1) to (3): (1) a step of preparing the urinary sediment sample liquid by separating urinary sediment from urine collected from a test subject and solubilizing podocalyxin in the urinary sediment; (2) a step of calculating a podocalyxin excretion amount in the urinary sediment sample liquid through detection of podocalyxin in the urinary sediment sample liquid; and (3) a step of calculating the number of urinary podocytes by dividing the podocalyxin excretion amount in the urinary sediment sample liquid by a podocalyxin amount per podocyte.

Abstract: Platform technology involving aqueous microdroplet reaction vessels created, arrayed, and characterized by imaging microscopy in a microfluidic device are applied to a wide variety of bioassays involving the detection and phenotypic characterization of single cells. The bioassays include the rapid and automated detection of microbial pathogens and their antibiotic sensitivity from patient samples as well as the characterization of immune responses using a patient's own cells, including the killing of tumor cells.

Abstract: The present invention provides, inter alia, a device comprising a colorimetric detection layer configured to undergo a color change upon interaction with a first analyte of interest. The detection layer comprises a first plurality of self-assembled fiber bundles. At least a fraction of the fiber bundles undergo a change from a first conformation to a second conformation upon interaction with the first analyte of interest, thereby undergoing a color change. The invention also provides a method for using the system to detect an analyte of interest.

Abstract: This invention is in the field of homeostasis analysis. More particularly, it relates to systems and methods for analyzing persistent homeostatic perturbations, i.e. chronic stress, by measuring levels of biomarkers that are related to chronic stress. This invention is also directed to systems and methods for analyzing the molecular mechanisms of chronic stress.

Abstract: Isolated truncated and mutated sensor proteins derived from flavoproteins that are 12-20 KDa or less, genetically encoded for detection and imaging of protein complexes having long fluorescent lifetimes that can be 4.0 ns or greater.

Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.